Accredited CME Program
MODERATOR
Jean M. Connors, MD
Medical Director, Hemostatic Antithrombotic Stewardship
Medical Director, Anticoagulation Management Services (Hematology Division)
Brigham and Women’s Hospital/Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts, United States
FACULTY |
FACULTY |
AlokA. Khorana, MD Professor of Medicine Cleveland Clinic Lerner College of Medicine Case Western Reserve University Sondra and Stephen Hardis Chair in Oncology Research Vice Chair, Clinical Services Director, Gl Malignancies Program Taussig Cancer Institute Cleveland Clinic Cleveland, Ohio, United States |
Jeffrey l. Weitz, MD, FRCP(C), FACP, FCCP Professor of Medicine and Biochemistry McMaster University Hamilton, Ontario, Canada |
Slide presentation: Evaluating Evolving Approaches to Treating Thrombosis in Cancer SLIDE
Burden of Cancer-Associated Thrombosis
Cancer-Associated Thrombosis = Arterial Venous Thrombosis
Mechanism of Thrombosis is Different in Cancer Patients
Choosing Between the Agents
CLOT Trial and the FDA-Approved LMWHs
Choosing Between the Agents
Choosing Between the Agents
Guideline Recommendations for Treatment of CAT-VTE
Weighing the Treatment Options
Considerations for Anticoagulation Therapy in Cancer Patients
The CARAVAGGIO Study
Finding the Right Therapy
Treatment Individualization and Shared Decisions
Though LMWH Is Preferred for High Risk of Bleeding…
Adherence/Treatment Persistence is an Issue
Limitations of Standard Care
Data from RCTs Comparing DOACs and LMWH in CAT
Why Target Factor XI?
Anticoagulants, Hemostasis, and Thrombosis
FXI
Uncoupling Thrombosis From Hemostasis
Targeting the Instrinsic Pathway
Clotting Cascade
Factor XI Targets
Phase 3 Clinical Trials Targeting Factor XI for CAT
Emerging Clinical Trials Targeting Factor XI – Phase 3
Other Studies Targeting Factor XI
FXI
Uncoupling Thrombosis from Homeostasis: Future Uses